Shares of Intra-Cellular Therapies Inc (ITCI, Financial) surged 12.31% in mid-day trading on Oct 30. The stock reached an intraday high of $87.70, before settling at $86.20, up from its previous close of $76.75. This places ITCI 1.71% below its 52-week high of $87.70 and 86.98% above its 52-week low of $46.10. Trading volume was 1,067,223 shares, 225.8% of the average daily volume of 472,566.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 15 analysts, the average target price for Intra-Cellular Therapies Inc (ITCI, Financial) is $96.17 with a high estimate of $130.00 and a low estimate of $74.00. The average target implies an upside of 11.57% from the current price of $86.20. More detailed estimate data can be found on the Intra-Cellular Therapies Inc (ITCI) Forecast page.
Based on the consensus recommendation from 17 brokerage firms, Intra-Cellular Therapies Inc's (ITCI, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Intra-Cellular Therapies Inc (ITCI, Financial) in one year is $199.98, suggesting a upside of 132% from the current price of $86.2. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Intra-Cellular Therapies Inc (ITCI) Summary page.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
